AAFP hires Hanaway to succeed Melton

Share this article:
The American Academy of Family Physicians has named ex-Ascend publisher Stephanie Hanaway to lead its titles, taking over for Joetta Melton, who is retiring.

Hanaway becomes publisher, American Family Physician and Family Practice Management, and director of publications. She reports to Michael Springer, VP publishing and communications.
“She has a very diverse background,” said Springer, “with a lot of experience in ancillary products and advance media, and we're delighted to have found her in our own back yard.” AAFP, like Ascend, is located in the Western medical publishing mecca of Overland Park, KS.

Hanaway spent most of her 20-year career in medical publishing at Intertec and Primedia, where she rose to VP, ancillary products before joining Ascend, which was founded by a trio of Primedia veterans. There, she worked as director of media sales for the events media division before leaving in August.

“I was familiar with AAFP's high standards of excellence, and when I learned of this opening, I had to jump on it,” said Hanaway.

Melton, who has been with AAFP for 20 years, will stay on until January 15 for a smooth transition. Under her direction, American Family Physician has been a reliably strong performer in an ugly market for primary care titles. In 2005, MM&M named the title Medium of the Year as it beat out all others in readership and ad exposures.      

Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union